Evidence map›Paper›PMID 41691453›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

NK Cell Activation by Platinum Boosts Immunotherapy in HR

Yi-Yu Chen, Yi-Fan Zhou, Xuan Qi, Ya-Xin Zhao, Tong Fu, Xi Jin, Minhong Shen, Yi-Zhou Jiang, Zhi-Ming Shao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Decoding the breast cancer microenvironment by spatial multi-omics: from architecture to clinical translation.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. NK Cell Activation by Platinum Boosts Immunotherapy in HRAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yi-Yu ChenKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yi-Fan ZhouKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Xuan QiKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Ya-Xin ZhaoKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Tong FuKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Xi JinKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Minhong ShenKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yi-Zhou JiangKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0003-3699-2630
Zhi-Ming ShaoKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-4503-148X

Funding

Clinical Cohort Shanghai SHDC2025CCS018Clinical Research Plan of SHDC SHDC2024CRI025National Natural Science Foundation of China 2021hwyq55National Natural Science Foundation of China 82373184National Natural Science Foundation of China 8244102National Natural Science Foundation of China 82472950Natural Science Foundation of Shanghai 23ZR1411800Shanghai Anticancer Association EYAS PROJECT SACA-CY25A01Shanghai Oriental Talent Program QNKJ2024015Shanghai Rising-Star Program 24QA2701400
6 · The paper itself

Abstract

Immunotherapy revolutionizes cancer therapeutics but shows limited efficacy in hormone receptor-positive (HR

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesImmunotherapyKiller Cells, NaturalPlatinumAnimalsCell Line, TumorFemaleHumansLymphocyte ActivationMiceTumor MicroenvironmentERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPlatinumHR+/HER2− breast cancerimmune checkpoint inhibitorsimmunotherapyNK cellsplatinum therapy

Identifiers

PMID41691453
PMCPMC13067780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.